Drug Type Small molecule drug |
Synonyms DAPAGLIFLOZIN/SAXAGLIPTIN, DAPAGLIFLOZIN/SAXAGLIPTIN HYDROCHLORIDE, Saxagliptin/Dapagliflozin + [2] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (15 Jul 2016), |
Regulation- |
Molecular FormulaC39H50ClN3O8 |
InChIKeyWFWDTDGSGQMZNG-ZNWYVNHESA-N |
CAS Registry2295810-36-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | EU | 15 Jul 2016 | |
Diabetes Mellitus, Type 2 | IS | 15 Jul 2016 | |
Diabetes Mellitus, Type 2 | LI | 15 Jul 2016 | |
Diabetes Mellitus, Type 2 | NO | 15 Jul 2016 |